Health Outcomes & Pharmacy Practice

Faculty

Photo

Rascati, Karen L., Ph.D.
Stewart Turley/Eckerd Corporation Centennial
Endowed Professor of Health Outcomes
& Pharmacy Practice
PHR 3.210D
512-471-1637
krascati@austin.utexas.edu


Selected Recent Publications

  1. Rascati KL, Richards K, Lopez D, Cheng LI, Wilson JP. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database. Accepted for Diabetes, Obesity, and Metabolism for 2013.

  2. Desai P, Lawson KA, Barner J, Rascati KL. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. Accepted by Journal of Managed Care Pharmacy 2013 (#13-007R).

  3. Chandwani HS, Strassels SA, Rascati KL, Lawson KA, Wilson JP. Estimates of charges associated with emergency department and hospital inpatient care for opioid abuse-related events.  Accepted by Journal of Pain and Palliative Care Pharmacotherapy Vol 27 (Issue 3) Sept 2013.

  4. Makhinova T, Rascati KL. An update on pharmacoeconomic education for Doctor of Pharmacy students in US schools and colleges of pharmacy. Accepted by the American Journal of Pharmaceutical Education for 2013.

  5. Oladapo A, Barner J, Rascati KL. The need for more evidence-based studies to justify the economic value for the provision of medication therapy management and other clinical pharmacy services. Clinical Therapeutics; 2012: 34(11):2196-2199.

  6. Park H, Park C, Kim YA, Rascati KL. Efficacy and safety of dipeptidyl peptidase-4 [DPP-4] inhibitors in type 2 diabetes: Meta-analysis. Annals Pharmacotherapy 2012: 46 (11), p 1453-1469.
    Gavaza P, Rascati KL, Aladapo A, Khoza S. The State of Health Economic Research in South Africa. Pharmacoeconomics, 2012: 30 (10); 925-940.

  7. Tiwana S, Rascati, KL, Park H. Cost-effectiveness of expanded newborn screening in Texas. Value In Health: The Journal of The International Society For Pharmacoeconomics And Outcomes Research, 2012: 15(5), 613-621.

  8. Park H, Rascati K, Prasla K, McBayne T. Evaluation of health care costs and utilization patterns for patients with gout. Clinical Therapeutics, 2012: 34(3), 640-652.

  9. Cheng L, Rascati K. Impact of Medicare part D for Medicare-age adults with arthritis: Prescription use, prescription expenditures, and medical spending from 2005 to 2008. Arthritis Care & Research, 2012: 64(9), 1423-1429. doi:10.1002/acr.21696

  10. Khoza S, Barner, J, Bohman T, Rascati K, Lawson K, Wilson J. Use of antidepressants and the risk of type 2 diabetes mellitus: a nested case-control study. International Journal of Clinical Pharmacy, 2012: 34(3), 432-438.

  11. Khoza S, Barner, J, Bohman T, Rascati K, Lawson K, Wilson J. Use of antidepressant agents and the risk of type 2 diabetes. European Journal of Clinical Pharmacology, 2012: 68(9), 1295-1302.

  12. Koranek A, Smith T, Mican L, Rascati K. Impact of the CATIE trial on antipsychotic prescribing patterns at a state psychiatric facility. Schizophrenia Research, 2012: 137(1-3), 137-140.

  13. Oladapo A, Barner, Rascati K, Strassels S. A retrospective database analysis of neuropathic pain and oral antidiabetic medication use and adherence among Texas adults with type 2 diabetes enrolled in Medicaid. Clinical Therapeutics, 2012: 34(3), 605-613.

  14. Adeyemi A, Rascati K, Lawson K, Strassels S. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis. Clinical Therapeutics, 2012: 34(3), 712-719.

  15. Dessi P, Chandwani H, Rascati, K. Assessing the quality of pharmacoeconomic studies in India: a systematic review. Pharmacoeconomics, 2012: 30(9), 749-762.

  16. Park H, Rascati K, Keith M, Hodgkins P, Smyth M, Goldsmith D, Akehurst R. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value In Health: The Journal of The International Society For Pharmacoeconomics And Outcomes Research, 2011:14(8), 1002-1009.

  17. Rascati KL, Richards K, Lopez D, Cheng L, Wilson J. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database. Clinical Therapeutics, 2011: 33(12), 2016-2020.

  18. Gavaza P, Brown CM, Lawson KA, Rascati KL, Wilson JP, and Steinhardt M. Examination of Pharmacists' Intention to Report Serious Adverse Drug Events (ADEs) to the FDA using the Theory of Planned Behavior. Research in Social and Administrative Pharmacy 2011: 7(4), 369-382.       

  19. Kim YA, Loucks A, Lightwood J, Yokokyama G, Rascati K, Serxner S. Evaluation of a value-based insurance design in a large retail employer: impact of adherence, utilization and costs. American Journal of Managed Care 2011;17 (10):682-690.

  20. Rascati KL, Richards KM, Ott CA, Goddard AW et al. Adherence, Persistence of Use, and Costs Associated with Second-Generation Antipsychotics for Bipolar Disorder, Psychiatric Services , September 2011; Vol. 62, No. 9.

  21. Kim Y, Rascati K, Prasla K, Godley P, Goel N, Dunlop D. Retrospective evaluation of the impact of copayment increases for specialty medications on adherence and persistence in an integrated health maintenance organization system. Clinical Therapeutics May 2011: 33(5):598-607


More Information About Dr. Rascati
> Current Position
> Books / Book Chapters
> Selected Recent Invited Presentations
> Selected Recent Research Presentations
> Return to Rascati's Home Page

Last Reviewed: May 16, 2013

Division Information

Mailing Address:
Pharmacy Practice
The University of Texas
at Austin
2409 University Ave.
Stop A1900
Austin, TX, USA
78712-1113

Email Address: pharmacy
@austin.utexas.edu

Phone:
1-512-232-2622

Division Information

Mailing Address:
Pharmacy Practice
The University of Texas
at Austin
2409 University Ave.
Stop A1900
Austin, TX, USA
78712-1113

Email Address: pharmacy
@austin.utexas.edu

Phone:
1-512-232-2622

index of the major headings: a b c d e f g h i j k l m n o p q r s t u v w x y z